XBiotech Inc.

NASDAQ:XBIT

Biotechnology

Healthcare
$1.73 -0.84%

-$0.02 today

Market cap
$52.74M
Beta
0.84
P/E (TTM)
-1.8
EPS (TTM)
-$1.32
52W Low $2.09High $3.61

Volume 0.06M

Average 0.03M

XBIT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

XBiotech Inc.NASDAQ: XBIT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2022
83.8%
Year-over-year change
+15.4pp

Gross Margin vs competitors

How XBIT compares with its peers on the latest reported figures

XBIT Competitors Peer median
Gross Margin for XBIT and competitors
Company Period LTM level YoY 3-year change
TCRXTScan Therapeutics, Inc.LTM Mar 202692.4% -7.6 pp-27.8 pp
FBIOFortress Biotech, Inc.LTM Mar 202664.5% +3.3 pp+7.6 pp
NTRBNutriband Inc.LTM Apr 202628.4% -4.9 pp-8.3 pp
ADAGAdagene Inc.LTM Jun 2024-14.6% —+0.0 pp
XBITXBiotech Inc.FY2025— ——
RLMDRelmada Therapeutics, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding XBIT) 46.4%-4.9 pp-4.1 pp

Competitors are the stored peer set for XBIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.39M4.01M000
Cost of Revenue5.82M651K001.69M
Gross Profit12.57M3.36M00(1.69M)
Gross Margin68.4%83.8%———
Research & Development28.27M31.54M32.85M37.76M47.39M
Selling, General & Admin9.39M6.31M4.66M4.71M8.3M
Operating Expenses37.66M37.85M37.51M42.47M54M
Depreciation & Amortization2.65M2.61M1.74M1.75M1.69M
EBITDA(22.81M)(30.97M)(22.57M)(36.01M)(43.53M)
EBITDA Margin-124.0%-772.4%———
Operating Income(25.08M)(34.49M)(37.51M)(42.47M)(55.69M)
Operating Margin-136.4%-860.1%———
Interest Income467K3.82M10.42M9.81M5.68M
Interest Expense000807K88K
Other Income / Expenses(376K)902K13.2M3.91M10.38M
Income Before Tax(25.46M)(33.59M)(24.31M)(38.56M)(45.31M)
Pre-Tax Margin-138.4%-837.6%———
Income Tax Expense(8.04M)(688K)244K(32K)235K
Net Income(17.41M)(32.9M)(24.56M)(38.53M)(45.54M)
Net Margin-94.7%-820.4%———
EPS (Basic)(0.58)(1.08)(0.81)(1.26)(1.49)
EPS (Diluted)(0.58)(1.08)(0.81)(1.26)(1.49)
Weighted Avg Shares30.04M30.44M30.32M30.46M30.49M
Weighted Avg Shares (Diluted)30.04M30.44M30.44M30.46M30.49M

XBiotech Inc.

NASDAQ:XBIT

Intrinsic Alpha fair value

Locked

Current Price

$1.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.